Quality of life in hemodialysis.
DOI:
https://doi.org/10.35954/SM2001.23.1.7Keywords:
Quality of Life; Hemodialysis; Chronic renal failure; Karnofsky.Abstract
Hemodialysis (HD) as a replacement treatment for renal function has considerably prolonged the life of chronic renal failure (CRF). We must now analyze the quality of life we offer them and whether it needs to be improved. To this end, a translation and adaptation of the Sicknes Impact Profile (Bergner, 1977) was made and a computer program (CALCSIP-I) was developed to calculate the global (EG), physical (EF) and psycho-social (EPS) scores, developed in CLIPPER, for MS-DOS and 386 or higher processor. Sixty-five CKD in HD, from 3 dialysis centers, were assessed with our adaptation of the SIP and the Karnosky Index (KI). The mean age was 55+-17 years, 39 (60%) male and 26 female, with an average time on HD of 47+-42 months. Of the group 6/65 were diabetic (D) and the remaining non-diabetic (non-D). The mean income was 3.9+-2 national minimum wage (SMN) which was taken equal to $ 525 (U$S 87). The EG of the SIP was 19.8+-15 points, the EF 15.8+-9 and the EPS 22.5+-16 points. Of the group 19/65 (29%) presented an EG between 0-10, 24/65 (37%) between 11-20, 10/65 (15%) between 21-30 and the remaining 12/65 (18.5%) greater than 31. According to Ht, the EG was: Ht=< 25% (N=17), 26+-17; Ht between 26-31% (N=26), 19.7+-18 and Ht> 31%, 14+-8 (p = 0.003). The EG was, according to their income, in the < 3SMN (N=26) 26+-18 and in the > 3SMN (N=39) 16+-12 ( p = 0.01). The D (N=6) had an EG of 27+-18 and the non-D (N=59) 19+-15 (p= 0.2). The IK was 80+-18; 44/65 (68%) =or> of 80 (rehabilitated), of which 32/65 (49%) was =or> of 90. In the Ds the score was 60+-15 and in the non-Ds 82+-17 (p= 0. 003); of the non-Ds 44/59 (75%) had a score 75, 8/59 (14%) of 70 and 7/59 (12%) <70; in the Ds (N=6), none had a score >70, in 3/6 it was =70 and in 3/6 <70. A negative linear relationship was found between the EG values of the SIP and the IK, with a correlation coefficient of -0.91 and an R2 of 0.84. We believe that our adaptation of the SIP is valid and both the SIP and its calculation program are useful tools for analyzing the quality of life of CKD on HD. Preliminary analysis of some of the data collected suggests that the most affected patients are those with lower Ht, lower income and diabetics.
Downloads
Metrics
References
(1) APOLONE G, MOSCONI P. Review of the concept of Quality of Life assessment and discussion of the present trend in clinical reserch. Nephrology,Dialysis and Tranplantation 13(Suppl.1):65,1998.
(2) TESTA MA, SIMONSON DC. Assessement of quality-of-life outcomes. N Eng J Med 1996; 334:835.
(3) BERGNER M, BOBBIT RA, CARTER WU, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19:787.
(4) HARRIS LE, LUFT FC, RUDY DW, et al. Clinical correlates of functional status in patients with chronic renal insuffiency. Am J Kid Dis 1993; 21:161.
(5) HART LG, EVANS RW. The functional status of ESRD patients as measured by the Sickness Impact Profile. J Chron Dis 40(sup 1):117S,1987.
(6) IFUDU O, PAUL H, MAYERS JD et al. Pervasive failed rehabilitation in centerbased maintenance hemodialysis patients. AmJ Kid Dis 1994; 23:394.
(7) MORENO F, LOPEZ JM, SANZ-GUAJARDO D, et al. Evaluation of the quality of life in dialysis patients. Results of the Spanish National Study of Quality of Life in Dialysis. Abstracts, XIII International Congress of Nephrology, Madrid (Spain), 1995, pag. 561.
(8) MORENO F, SANZ-GUAJARDO D, LOPEZ JM. et al. The relation of haemoglobin on quality of life in patients with ESRD on dialysis. Spanish National Study on Quality of Life on Dialysis. Abstracts, XIII International Congress of Nephrology, Madrid (Spain), 1995, pag. 509..
(9) MORENO F, ARACIL FJ, PEREZ R, VALDERRABANO F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kid Dis 27:548,1996.
(10) KARNOFSKY DA, BURCHENAL JH. The clinical evaluation of chemotherapeutic agents in cancer. En: Evaluation of chemotherapeutic agents. Editor CM Macleod, New York, Columbia Univ. Press, año 1949, pagina 191.
(11) EVANS RW, MANNINEN DL, GARRISON LP et al The quality of life of patients with end-stage renal disease. N Eng J Med 312:553,1985.
(12) CARLSON DM, JOHNSON WJ, KJELLSTRAND CM. Functional status of patients with end-stage reanl failure. Mayo Clin Proc 62:338,1987.
(13) ALEXANDER JL, WILLEMS EP. Quality of life: some measurements requirements. Arch Phys Med Rehabil 62:261,1981.
(14) SCHWARTZMANN L, DERGAZARIAN S, GUERRA A et al. Analisis conceptual de instrumentos para medir calidad de vida en HDC. Resumen. Publicacion del III Congreso Uruguayo de Nefrologia, Montevideo, 1995.
(15) GOKAL R. Quality of life in patients undergoing renal replacement therapy. Kid Int 43:523,1993.
(16) HENDRICSON WD, RUSSELL IJ, PRIHODA TJ, et al. An approach to developing a valid spanish language translation of a health status questionnaire. Med Care 27:959, 1989.
(17) GUTMAN RA, STEAD WW, ROBINSON RR. Physical activity and employement status of patients on maintenance dialysis. NEngJMed 304:309, 1981.
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
